What is retatrutide?
Retatrutide (LY3437943) is a synthetic peptide engineered by Eli Lilly to simultaneously activate three metabolic hormone receptors: GLP-1, GIP, and glucagon. It is the first triple-hormone-receptor agonist to advance through Phase 3 clinical trials — a genuine first in the metabolic therapeutics space. Once-weekly subcutaneous injection.
The results are the largest ever reported in a Phase 3 obesity trial. In TRIUMPH-4 (December 2025 topline): 28.7% mean body weight reduction at 68 weeks at the 12 mg dose. 39.4% of participants achieved ≥30% weight loss. For comparison: semaglutide (Wegovy) produces roughly 15% at peak doses, tirzepatide (Zepbound) roughly 20–22%. The Phase 2a MASLD substudy showed 82% liver fat reduction at 24 weeks — one of the most striking fatty liver results ever reported. And TRIUMPH-4 showed up to 75.8% reduction in knee osteoarthritis pain scores. For people who have struggled with obesity, metabolic dysfunction, visceral fat, or weight-related conditions, retatrutide represents a meaningful step forward in what's pharmacologically possible.
What makes retatrutide different from its predecessors is the third receptor arm — glucagon. GLP-1 agonism suppresses appetite and slows gastric emptying (the shared mechanism across the entire class). GIP agonism improves insulin sensitivity and modulates adipose tissue (the differentiator that allowed tirzepatide to outperform semaglutide). Glucagon receptor agonism does something neither of the first two do: it increases basal energy expenditure — you burn more at rest — and directly drives lipolysis of liver and visceral fat. Three levers instead of two. The pharmacological achievement is balancing glucagon's glucose-raising effect against GLP-1 and GIP's glucose-lowering effects, which earlier triple-agonist attempts couldn't solve. Retatrutide solved it.
As of May 2026, retatrutide is not approved anywhere in the world. It is under active Phase 3 investigation by Eli Lilly, with seven additional readouts expected through 2026 and earliest plausible FDA approval in the 2026–2027 window. It is being widely sourced through grey-market and compounding channels in the meantime. The approved version will come with verified manufacturing quality, medical supervision through dose titration, and monitoring for serious adverse events. For most people, waiting for approved access captures the full benefit without the avoidable risks of off-market sourcing. For those who have decided otherwise — and there is a real and growing community doing exactly that — the right approach is as much medical oversight as possible, slow titration, and careful tracking of everything that changes.
How it works
GLP-1 Receptor Agonism — Lever 1: Appetite Suppression
GLP-1 is an incretin hormone your gut releases after meals. Retatrutide's GLP-1 receptor activation suppresses appetite centrally — via the hypothalamus and brainstem — slows gastric emptying to extend satiety, and enhances glucose-dependent insulin secretion. This is the shared mechanism across the entire GLP-1 class: semaglutide, liraglutide, and the GLP-1 component of tirzepatide all work this way.
GIP Receptor Agonism — Lever 2: Insulin Sensitivity and Adipose Modulation
GIP is the second major incretin. Its receptors sit on pancreatic beta cells, adipose tissue, and in the central nervous system. GIP receptor agonism is what allowed tirzepatide to outperform semaglutide in head-to-head trials — the exact mechanism by which GIP enhances weight loss when combined with GLP-1 is still being characterized, but the effect is well-established.
Glucagon Receptor Agonism — Lever 3: Energy Expenditure and Direct Lipolysis
This is the arm that makes retatrutide mechanistically new. At physiologic doses, glucagon receptor activation increases basal energy expenditure — raising metabolic rate — and drives direct lipolysis of stored triglycerides, particularly in liver and visceral fat. Combined with GLP-1 and GIP (which together lower blood glucose), the glucagon arm's calorigenic and lipolytic effects come through without worsening glycemic control. The Phase 2 type 2 diabetes trial confirmed this: meaningful HbA1c reductions even with glucagon activation. That balance is the core pharmacological achievement of retatrutide.
Why the Liver Fat Data Matters
The 82% liver fat reduction at 24 weeks in the Phase 2a MASLD substudy isn't simply a consequence of overall weight loss. Glucagon receptor agonism directly drives hepatic lipolysis — the drug is mechanistically pulling fat out of the liver, not just shrinking it through caloric deficit. This makes retatrutide one of the most targeted interventions available for metabolic dysfunction-associated steatotic liver disease (MASLD).
Dosing and Pharmacokinetics
Once-weekly subcutaneous injection. Dose titration is standard protocol — starting at 2 or 4 mg and escalating to therapeutic doses (8 mg, 12 mg) over several weeks to manage gastrointestinal side effects. The 9 mg and 12 mg doses were both studied in TRIUMPH-4; the marginal weight-loss difference (26.4% vs. 28.7%) came with meaningfully different adverse-event dropout rates (12.2% vs. 18.2%).
What the research shows
HUMAN EVIDENCE
What the community reports
The retatrutide user community is large, growing, and unusually well-informed — many users have prior experience with semaglutide and tirzepatide and are bringing that comparison context to their protocols. The reports are consistent enough to constitute a meaningful real-world signal alongside the clinical data.
The retatrutide community is generating real practical knowledge that formal trials don't capture: which titration speeds minimize GI side effects, what to eat during escalation, how to preserve muscle mass, how to manage the psychological adjustment to dramatically reduced appetite. This practical knowledge — built by users with the comparison experience of having run semaglutide and tirzepatide — is worth tracking alongside the clinical evidence.
Biology is individual. The trial data tells you what happens on average across hundreds of participants. What happens to you — at your dose, with your metabolism, your baseline, your lifestyle — is the data that matters most for your own protocol. Track carefully, especially during titration.
Common misconceptions
"Retatrutide is just a stronger version of tirzepatide."
Mechanistically different, not just stronger. Tirzepatide is a GLP-1/GIP dual agonist; retatrutide adds glucagon receptor agonism. The glucagon arm contributes increased energy expenditure and direct lipolysis of liver and visceral fat — mechanisms tirzepatide doesn't engage. The larger weight loss isn't dose escalation; it's an additional pharmacological lever.
"If the data is this good, it should already be approved."
Drug approval requires Phase 3 trials to read out and be peer-reviewed, FDA review of a BLA, post-marketing safety planning, and manufacturing scale-up. The first Phase 3 topline was December 2025; seven more readouts are expected through 2026. Earliest plausible approval is 2026–2027. Strong data doesn't shortcut the process.
"Compounded retatrutide is legal the same way compounded semaglutide was."
Compounded semaglutide had a narrow legal pathway via FDA shortage-list provisions. Retatrutide has never been an FDA-approved drug — it has never been on the shortage list — so the shortage-based compounding exemption does not apply. Compounders selling retatrutide are operating outside that legal framework.
"The weight loss is permanent once you stop."
No published long-term post-discontinuation data exists yet. The pattern with semaglutide and tirzepatide is significant weight regain after stopping. There is no reason to expect retatrutide will be different — its effects are active while the drug is in your system. Long-term use or a carefully planned discontinuation strategy is likely required to maintain results.
"The 12 mg dose is always better than 9 mg."
In TRIUMPH-4, the 9 mg dose produced 26.4% weight loss with 12.2% adverse-event dropout. The 12 mg dose produced 28.7% weight loss with 18.2% dropout. The marginal 2.3% additional weight loss may not justify the increased side effect burden for many people. Dose individualization — ideally with a clinician — matters.
Open PepperLedger to track your GLP-3 protocol and ask the Coach →
Free to join. No credit card. Ask the Coach about retatrutide once you're in.
Free to join · No credit card · 23-day Pro trial included